诺瓦瓦克斯医药(NVAX)公司股价在11月11日盘前大涨13.13%,引发市场关注。这一大涨与美国食品和药物管理局(FDA)最新决定解除对该公司新冠流感疫苗及独立流感疫苗后期临床试验限制密切相关。
根据路透社报道,Novavax公司周一表示,FDA已经取消了对其COVID-流感复合疫苗及独立流感疫苗后期临床试验的限制。此前FDA曾基于一些安全隐患,对这两款疫苗的试验做出了限制。
FDA此次决定解除限制,意味着Novavax公司的疫苗研发项目将重回正轨,并为其商业化推广扫清了重大障碍。作为新型疫苗研发领域的后起之秀,Novavax公司一直备受资本市场的关注。此次利好消息无疑令投资者对公司前景重燃信心,从而推动股价出现大涨行情。
展望未来,如果Novavax公司能够借此机会顺利通过临床试验,其新型疫苗产品有望在未来一两年内取得上市许可并开启销售。作为新冠疫苗和流感疫苗的复合型产品,该疫苗无疑将成为该公司未来重要的利润增长点。毫无疑问,这一利好消息为公司发展前景增添了新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.